**Odylia Therapeutics** is accelerating the development of therapies for people with rare diseases by changing the way treatments are brought from the lab to patients, regardless of prevalence. As a nonprofit biotech, Odylia is shifting the paradigm to focus on proven science and removing roadblocks.

**The Challenge**
Developing gene therapies for rare diseases is a long, slow process, often stalled by the high costs for drug development and manufacturing, and the low commercial interest or lack of expertise. Ultimately, viable treatments are left ‘on the shelf’ and never used to treat patients.

**Odylia’s Mission**
Odylia Therapeutics works to lower costs, reduce development time, focus research, and continuously drive successful programs to clinical trials and regulatory approval. Strategic collaborations with patient groups, research labs, and commercial partners facilitate our work to ensure treatments are safe, effective, and reach patients. Our initiatives include:

- **Gene Therapy Pipeline** - Odylia creates and implements streamlined, strategic plans, to move gene therapies through preclinical development to clinical trials. We direct the critical activities required to ensure roadblocks are removed and efficiency is maximized.

- **Manufacturing Fund** - to ensure treatments don’t stall, Odylia is forging a new path. We are consolidating philanthropic donations of all sizes, to fund the costs of physically manufacturing gene therapies for patients with rare diseases. This will also advance a gene therapy platform that will be available to other nonprofits and strategic partners.

- **Brydge Solutions** - Patient Advocacy Groups are the primary drivers of rare disease research. These grass-root efforts often lack the bandwidth and scientific knowledge to determine the best plan to move research from the lab to clinical trials, resulting in loss of valuable time and resources. Odylia enables these groups to build capacity by working hand-in-hand to develop a research roadmap, gap analysis, clinical development planning, and other tools critical to achieving each group’s goals.

**How You Can Help**
Philanthropic support enables us to keep treatments moving toward clinical trials. As a nonprofit, the bulk of our funding comes from individuals and companies who believe in our mission and want to join our efforts to impact the lives of patients. Our most urgent need is to raise funds to finish the preclinical work on our pipeline programs. Without financial support, life-altering treatments may never reach the patients who need them. You can make a donation, become a corporate partner, or contact us to explore other ways to support Odylia’s mission. We look forward to hearing from you at hgreene@odylia.org.